Pharma strategy digest
1.3K views | +0 today
Follow
Pharma strategy digest
A treasure trove of golden nuggets and pearls of wisdom for pharmaceutical industry strategists and newshounds.
Curated by Tim Mustill
Your new post is loading...
Your new post is loading...
Rescooped by Tim Mustill from Digital Health
Scoop.it!

Former Apple CEO on why health tech startups don't tackle the big problems

Former Apple CEO on why health tech startups don't tackle the big problems | Pharma strategy digest | Scoop.it
John Sculley, who served as CEO of Apple from 1983 to 1993 and before that as president of PepsiCo, is now trying to upend the healthcare industry with RxAdvance, a cloud-based pharmacy benefits platform. "This is the most important thing I’ve done since I was involved at Apple," Sculley told Mashable. "It's the most exciting time in my life." Sculley, founding partner of RxAdvance, called Mashable to talk about the future of healthcare, why health tech startups aren't tackling the big picture and what entry into healthcare means for Apple.
Via Alex Butler
Tim Mustill's insight:

Not just big ideas lacking. More interdisciplinary collaboration is also needed.

more...
No comment yet.
Scooped by Tim Mustill
Scoop.it!

Results Healthcare - Blog : Biotech is booming, why the UK and Europe should follow in the footsteps of the US

Results Healthcare - Blog : Biotech is booming, why the UK and Europe should follow in the footsteps of the US | Pharma strategy digest | Scoop.it
Recently Sir John Bell took the opportunity afforded by his appointment to the board of Immunocore to highlight the lack of private investment in the...
Tim Mustill's insight:

This trans-Atlantic contrast in funding was also a theme at BioTrinity this week. More to follow on www.astorcyte.co.uk blog zone.

more...
No comment yet.
Rescooped by Tim Mustill from Digital Health
Scoop.it!

THE INTERNET OF THINGS (IOT) ECOSYSTEM: FOUR WAYS IT WILL IMPACT HEALTH

THE INTERNET OF THINGS (IOT) ECOSYSTEM: FOUR WAYS IT WILL IMPACT HEALTH | Pharma strategy digest | Scoop.it

My vision of a digital health revolution is in four parts, those being:

Access to information (the internet age)Access to each other (the socialised internet)Access to ourselves (the rise of quantified self, expressed through mobile and wearable health technology)Access to everyone (the subsequent development and application of big data)

 

What is interesting is that it is really a revolution in five parts, the final one is not as noisy as the previous four. It could even be called silent, but there is good reason to believe it will be the most important for the future of medicine, healthcare and well-being. This is the connectivity to everything. 


Via Alex Butler
Tim Mustill's insight:

Without help this revolution will by-pass the demographic that need it most ie the unwired, co-morbid, underprivileged elderly. Thankfully there are some companies out there trying to access these stakeholders eg http://www.seespeak.co.uk/

 

more...
No comment yet.
Rescooped by Tim Mustill from Pharmaguy's Insights Into Drug Industry News
Scoop.it!

Can You Trust Patient Rankings of #Pharma Corporate Reputation? Yes IMHO you can.

Can You Trust Patient Rankings of #Pharma Corporate Reputation? Yes IMHO you can. | Pharma strategy digest | Scoop.it

An independent study by PatientView

 

Findings based on a survey of 1,150 patient groups (from 58 countries and of differing specialties)Survey conducted mid-November 2014 to mid-January 2015Patient-group feedback on the corporate reputation of the entire pharma industry during 2014Patient-group feedback on the corporate reputation of 37 individual pharma companies in 2014Results for 2014 are compared with those of 2013, 2012, and 2011

 

The 37 pharma companies reviewed in the study are: AbbVie l Actavis l Allergan l Amgen l Astellas l AstraZeneca l Baxter International l Bayer l Biogen Idec l Boehringer-Ingelheim l Bristol-Myers Squibb l Celgene l Eisai l Eli Lilly (Lilly) l Gilead l GlaxoSmithKline (GSK) l Grũnenthal l Ipsen l Janssen l Lundbeck l Menarini l Merck & Co (USA) l Merck KgA (Germany) l Mylan l Novartis l Novo Nordisk l Otsuka l Pfizer l Roche l Sanofi l Servier l Shire l Stada Arzneimittel l Takeda l Teva l UCB l ViiV Healthcare

 

The corporate reputation of individual pharma companies (as seen from a patient perspective) shows some significant changes between 2014 and 2013 (37 companies assessed in 2014; 33 companies in 2013).


Via Pharma Guy
Tim Mustill's insight:

In response to Pharmaguy's 'speculation'. There is a close relationship between pharma companies and patient groups but not for the reasons he cited and certainly not to the point that it would bias the outcome.

more...
Pharma Guy's curator insight, February 14, 2015 7:53 AM


Several of the patient organizations participating in this survey receive funding from the pharmaceutical industry. This is common practice especially in the EU where pharma companies cannot promote product directly to consumers but must depend upon intermediaries such as patient organizations -- some of which pharma companies set up themselves -- to help them reach consumers. 


Also note that Lundbeck (after slumping to 22nd in 2013—almost certainly because patient groups reacted to the June 2013 news that the company had been fined by the European Commission) has managed to move back up the rankings in 2014 to 5th. How quickly patients forget! It's difficult to believe. More likely is that Lundbeck spread goodwill via increased grants to patient groups. I'm just speculating here.

Scooped by Tim Mustill
Scoop.it!

At the Mayo Clinic, IBM Watson Takes Charge of Clinical Trials - IEEE Spectrum

At the Mayo Clinic, IBM Watson Takes Charge of Clinical Trials - IEEE Spectrum | Pharma strategy digest | Scoop.it
The robo-doc will match patients to experimental treatments
Tim Mustill's insight:

Elementary.....!

more...
No comment yet.
Scooped by Tim Mustill
Scoop.it!

Impression Management – The Psychology of the Viral Ice Bucket Challenge

Impression Management – The Psychology of the Viral Ice Bucket Challenge | Pharma strategy digest | Scoop.it
Okay, so why has the charity Ice Bucket Challenge* become the viral sensation of Summer 2014, recruiting over 20 million views and a million participants including celebrity pop, screen and sports stars – Lady Gaga, LeBron James, Justin Bieber,...
Tim Mustill's insight:

Some pointers for on line impressions here. PLus interesting insight on IBC  (and I thought it was because my daughter nominated me). The figures in the infographic are out of date now btw - the ALS donated amount is >$60m!

more...
No comment yet.
Scooped by Tim Mustill
Scoop.it!

Content Marketing is Dead: Mathematical Proof

Content Marketing is Dead: Mathematical Proof | Pharma strategy digest | Scoop.it
Simple mathematics tells us that content marketing is dead. Why? Well given that the volume of content on the Web is growing exponentially, doubling every ...
Tim Mustill's insight:

OK the headline got me to the end of this (short) article. I disagree with the conclusion however as I think pharma can positively contribute to content. We may not be doing so but we could!

more...
No comment yet.
Scooped by Tim Mustill
Scoop.it!

[INFOGRAPHIC] M-Health Physician Use of Mobile Technology

[INFOGRAPHIC] M-Health Physician Use of Mobile Technology | Pharma strategy digest | Scoop.it
Tim Mustill's insight:

Usual mix of potentially useful stats and guff (250% more likely to own a tablet - so what!?)

more...
No comment yet.
Scooped by Tim Mustill
Scoop.it!

Researchers use 3-D printing to create synthetic blood vessels

Researchers use 3-D printing to create synthetic blood vessels | Pharma strategy digest | Scoop.it
Researchers at Boston's Brighman and Women's Hospital used a 3-D bioprinting method to create functional synthetic blood vessels that could someday be used develop transplanted tissues and test drugs outside the body.
Tim Mustill's insight:

Interesting stuff

more...
No comment yet.
Rescooped by Tim Mustill from e-Marketing for the healthcare sector
Scoop.it!

Infographic Connected Physician Primary Care Q1 2014 | Digital Insights Group

Infographic Connected Physician Primary Care Q1 2014 | Digital Insights Group | Pharma strategy digest | Scoop.it

Via Michael Lucht - www.b-innovative.eu
Tim Mustill's insight:

US PCP data - applicable to European Drs I wonder?

more...
No comment yet.
Scooped by Tim Mustill
Scoop.it!

I Dared Slate Readers to Read My Article to the End—and Some Did!

I Dared Slate Readers to Read My Article to the End—and Some Did! | Pharma strategy digest | Scoop.it
Last week I challenged readers to get to the end of my column. OK, right, I do that every week, but this time the challenge was explicit. The Web traffic–analysis firm Chartbeat had provided me with stats showing that most people don’t scroll all the way through online articles. At...
Tim Mustill's insight:

Interesting insight for the blogeratti in here (though original article is from last year). I especially like the comment about how folks feel they can forward or comment on something without having read it. Let's face it we've all done it but we can come unstuck if the short comment doesn't gel with the whole gist of the story.

For the record I am one of the 40% who made it through to the bottom of p2 on this one!

more...
No comment yet.
Scooped by Tim Mustill
Scoop.it!

Healthcare Innovation at SXSW | HealthWorks Collective

Healthcare Innovation at SXSW | HealthWorks Collective | Pharma strategy digest | Scoop.it
Last Friday marked the start of SXSW 2014 — a meeting that pulls together creatives and innovators from healthcare, media, film, tech and more, to learn, exchange ideas and provide a jolt to the collective creative energy that stimulates change.
Tim Mustill's insight:

Interesting challenge for healthcare providers and pharma alike in point 3. If we are slow to embrace digital we lose young talent to other sectors!

more...
No comment yet.
Scooped by Tim Mustill
Scoop.it!

Steve Ballmer's Advice for Startups

Steve Ballmer's Advice for Startups | Pharma strategy digest | Scoop.it
Steve Ballmer joined Microsoft in 1980 as the company’s first business manager, going on to replace Bill Gates as CEO in 2000. Before becoming CEO, his rol
Tim Mustill's insight:

Nice precis of the salieint points form today's lunch chat. Except the part where Tufano called him Bill!

more...
No comment yet.
Scooped by Tim Mustill
Scoop.it!

Innovations help meet the challenge of chronic diseases – Astrocyte Strategy in the Pharmaceutical and Healthcare Sector

Tim Mustill's insight:

This blog makes an appeal for open innovation and better sharing of new findings and research in order to tackle the increasing burden of illness associated with chronic conditions. There is also some sound advice for start-ups with regard to planning and funding.

more...
No comment yet.
Scooped by Tim Mustill
Scoop.it!

Results Healthcare - Blog : Cancer Vaccination is Making a Major Rebound

Results Healthcare - Blog : Cancer Vaccination is Making a Major Rebound | Pharma strategy digest | Scoop.it
"Cancer vaccination is making a major rebound. There are many exciting trials coming up based on preclinical data," said Drew Pardoll, an...
Tim Mustill's insight:

As noted in the article early efforts taught us a lot (and cost some players a lot too!)

more...
No comment yet.
Scooped by Tim Mustill
Scoop.it!

Embrace impermanence - maybe not just yet for big pharma!

Embrace impermanence - maybe not just yet for big pharma! | Pharma strategy digest | Scoop.it
Tim Mustill's insight:

An old adage which has been appropriated by mindfulness devotees. You'd think in a industry that often claims that 'the only constant is change' then such an aphorism would be attractive.

Or not (at least not yet!).

more...
No comment yet.
Scooped by Tim Mustill
Scoop.it!

PR Tufts CSDD 2014 Cost Study | Tufts Center for the Study of Drug Development

{my_page_description}
Tim Mustill's insight:

It was not so long ago (18mths to be precise) that Andrew Witty was telling us that the $1b per drug price tag was ‘a myth ’http://bit.ly/1xMkpJ7 and I have some sympathy with his viewpoint. This new Tufts report will fuel the debate on cost of drug development and the associated price of drugs once launched if we accept the new $2.6b cost estimate. I think this is a sterile debate however and we need to re-set the discussion around innovation in development and value in the market.

more...
No comment yet.
Scooped by Tim Mustill
Scoop.it!

The Reinvention Of Medicine: Dr. Algorithm V0-7 And Beyond | TechCrunch

The Reinvention Of Medicine: Dr. Algorithm V0-7 And Beyond | TechCrunch | Pharma strategy digest | Scoop.it
Editor's note: Vinod Khosla is an entrepreneur and investor. He is the founder of Khosla Ventures, which is focused on impactful sustainable energy and..
Tim Mustill's insight:

Somewhat gung-ho but interesting speculation here - apposite on the day care.data pilot is (re)-launched

more...
No comment yet.
Scooped by Tim Mustill
Scoop.it!

A computational and neural model of momentary subjective well-being

A computational and neural model of momentary subjective well-being | Pharma strategy digest | Scoop.it
Tim Mustill's insight:

A computational equation for happiness?? No - me neither, until I read that this fascinating bit of research was done at my alma mater (probably the best neuroscience dept in the world)

more...
No comment yet.
Scooped by Tim Mustill
Scoop.it!

The secret of successful drug launches | McKinsey & Company

The secret of successful drug launches | McKinsey & Company | Pharma strategy digest | Scoop.it
About two-thirds of drug launches don’t meet expectations. Improving that record requires pharmaceutical companies to recognize the world has changed and adjust their marketing accordingly. A McKinsey & Company article.
Tim Mustill's insight:

Not one to normally push the big boys insights but this report does make interesting reading - I quite like the launch archetypes (albeit not so sure about their noted % split across these quads).

more...
No comment yet.
Scooped by Tim Mustill
Scoop.it!

Health innovation: Big ideas

Health innovation: Big ideas | Pharma strategy digest | Scoop.it

od points davidI have worked continuously in the pharmaceutical sector for 30 years. During that time I have worked for three global pharmaceutical companies, and set up two healthcare communications groups with offices and businesses covering most regions of the...

Tim Mustill's insight:

Good points David. Wonder what Lord Seb Coe thinks? Oh hang on... we can ask him when  debating the implications of these issues at the Big Ideas meeting later today!

more...
No comment yet.
Scooped by Tim Mustill
Scoop.it!

Track Your Health | Wellness & Prevention, Inc.

Track Your Health | Wellness & Prevention, Inc. | Pharma strategy digest | Scoop.it
Tim Mustill's insight:

Sign of the time as J&J support 'meta-helathappage'!

more...
No comment yet.
Scooped by Tim Mustill
Scoop.it!

Digital life in 2025 – 15 predictions | Klick Health

Digital life in 2025 – 15 predictions | Klick Health | Pharma strategy digest | Scoop.it
The PEW Internet Project tapped some of the leading internet futurists plus thousands of users to come up with the top 15 trends we will see in 2025. Take a look at Klick Health's take on these trends as they relate to health.
Tim Mustill's insight:

Not actually 15 predictions but 5 short and sweet trends - the 'Ubernet' comment is pertinent and topical to UK Pharma. It is worth following the link to PEW to download the full (free ) report.

more...
No comment yet.
Scooped by Tim Mustill
Scoop.it!

More data, better drugs: Genentech, PatientsLikeMe ink groundbreaking research pact - San Francisco Business Times

More data, better drugs: Genentech, PatientsLikeMe ink groundbreaking research pact - San Francisco Business Times | Pharma strategy digest | Scoop.it
The five-year agreement is the first broad research collaboration between PatientsLikeMe and a drug company, but it also demonstrates how open-source research and social media are increasingly tapped by companies to get real-world insights into diseases and how patients respond to treatments.
Tim Mustill's insight:

Well done ITC - been advocating such a link for many clients for many months (not invented here syndrome oft kicked in however).

more...
No comment yet.
Rescooped by Tim Mustill from Marketing Revolution
Scoop.it!

Only 28% Brands Can Measure Content Marketing ROI

Only 28% Brands Can Measure Content Marketing ROI | Pharma strategy digest | Scoop.it

Almost two-thirds (63 per cent) of brands now have a dedicated content marketing budget, research from Bite has found, with 43 per cent of those surveyed saying content marketing was a board priority for their company


Via John van den Brink
Tim Mustill's insight:

No worse than print media imho!

more...
Martin (Marty) Smith's curator insight, March 17, 2014 8:59 PM

Yep, this infographic sounds and feels right to me. Fact I was surprised it was as high as a third :). Marty